SCHEMBL262863

SCHEMBL262863

COC(C)COc1ccc(F)cc1Br

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.50
MAPT P10636 10/20 0.41
RAB9A P51151 4/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
GAA P10253 1/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 7/20 0.37
LMNA P02545 2/20 0.37
ALDH1A1 P00352 1/20 0.37
HTT P42858 1/20 0.37
HPGD P15428 4/20 0.37
NPC1 O15118 3/20 0.37
TDP1 Q9NUW8 3/20 0.37
KDM4E B2RXH2 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14314644 0.82 MRGPRX4 (0.42) PKMKMT2AMEN1ALDH1A1HPGD
SCHEMBL20790230 0.82 L3MBTL1 (0.51) MAPTRAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL20789838 0.82 L3MBTL1 (0.51) MAPTRAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL20789839 0.82 L3MBTL1 (0.51) MAPTRAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL263217 0.81 KMT2A (0.53) MAPTRAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL29678622 0.76 PKM (0.49) PKMMAPTRAB9ASMN1; SMN2KMT2A
SCHEMBL4356588 0.76 PKM (0.49) PKMMAPTRAB9ASMN1; SMN2KMT2A
SCHEMBL29440624 0.76 PKM (0.56) PKMMAPTRAB9ASMN1; SMN2KMT2A
SCHEMBL972013 0.76 PKM (0.56) PKMMAPTRAB9ASMN1; SMN2KMT2A
SCHEMBL4355667 0.75 PKM (0.59) PKMMAPTRAB9ASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP disclosed
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP disclosed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 US disclosed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 US disclosed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 US disclosed
EP-2183241-A2 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS Pfizer Limited (GB) 2010-05-12 EP disclosed
CN-101675040-A 2-pyridinecarboxamide derivatives as sodium channel modulators PFIZER LTD 2010-03-17 CN disclosed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 US disclosed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 US disclosed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 US disclosed
WO-2008135826-A2 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LIMITED (GB) 2008-11-13 WO disclosed
WO-2008135826-A2 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LIMITED (GB) 2008-11-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048306-A1 PYRIDINE DERIVATIVES SDHA, P2RX4, P2RX3 PKM 204/4885MAPT 1692/4885RAB9A 2558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.